Form 4: Sangamo Therapeutics Director John Markels Receives Significant Equity Grants

John Markels, a Director at Sangamo Therapeutics, Inc., was granted 25,000 shares of common stock as Restricted Stock Units and 50,000 stock options with an exercise price of $0.503 on June 12, 2025.

Summary

• John Markels, a Director of Sangamo Therapeutics, Inc. (SGMO), acquired 25,000 shares of common stock through a Restricted Stock Unit (RSU) grant on June 12, 2025.
• These 25,000 RSU shares will fully vest on the earlier of June 12, 2026, or the day prior to the 2026 annual meeting of stockholders, contingent on Mr. Markels' continuous service.
• Following this transaction, Mr. Markels beneficially owns a total of 96,384 shares of common stock.
• Additionally, Mr. Markels was granted 50,000 stock options on June 12, 2025, with an exercise price of $0.503 per share.
• These stock options are immediately exercisable, but any unvested shares purchased are subject to repurchase rights by the Issuer.
• The 50,000 option shares will vest in 12 successive equal monthly installments following the grant date, subject to continuous service.
• The options have an expiration date of June 11, 2035.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive signal, indicating alignment of interests and incentivizing long-term performance. It's a routine compensation event, not a major market mover, hence a moderately positive score.

Positives

• The grant of 25,000 Restricted Stock Units and 50,000 stock options to Director John Markels aligns his interests with those of shareholders, incentivizing long-term performance.
• The immediate exercisability of the stock options, despite vesting conditions, provides flexibility for the director.

Negatives

• The vesting conditions for both the RSUs and stock options require continuous service, meaning the benefits are contingent on the director remaining with the company.
• Unvested shares purchased under the stock option are subject to repurchase rights by the Issuer, which could limit immediate liquidity or full ownership if service ceases.

Risks

• The vesting of both RSU shares and stock options is subject to the Reporting Person's Continuous Service, meaning the benefits are contingent on continued employment or board membership.
• Unvested shares purchased under the stock option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service, potentially limiting the full realization of the option's value if service is terminated prematurely.

Future Outlook

The document details equity grants to a director, which are part of a compensation plan designed to align management incentives with long-term company performance. The vesting schedules for both the RSUs and stock options extend into 2026 and 2035 respectively, indicating a long-term commitment framework for the director.

Industry Context

This Form 4 filing reflects a standard practice in the biotechnology and pharmaceutical industry, where equity grants like Restricted Stock Units and stock options are common components of executive and director compensation packages. These grants are used to attract and retain talent, and to align the interests of key personnel with the long-term success and shareholder value creation of the company, particularly in a sector with long development cycles and significant R&D investment like Sangamo Therapeutics.

Related Party Transactions

• The grant of 25,000 Restricted Stock Units and 50,000 stock options to John Markels, a Director of Sangamo Therapeutics, constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The equity grants aim to align the director's interests with shareholders, potentially leading to better long-term performance and value creation. However, it also represents potential future dilution if new shares are issued upon vesting/exercise.
• Employees: No direct impact mentioned, but such grants are part of a broader compensation philosophy that might influence employee incentive structures.

Next Steps

• The 25,000 RSU shares are expected to fully vest on the earlier of June 12, 2026, or the day prior to the 2026 annual meeting of stockholders, subject to continuous service.
• The 50,000 stock options will vest in 12 successive equal monthly installments following the grant date, subject to continuous service.
• The director may exercise the stock options at any time before their expiration on June 11, 2035, though unvested shares purchased are subject to repurchase rights.

Key Dates

Recommendation

Keywords

Sangamo Therapeutics, SGMO, Form 4, SEC filing, insider transaction, stock options, Restricted Stock Units, RSU, equity grant, director compensation, beneficial ownership, equity incentive plan